source
- Aclaris Therapeutics’ bosakitug fails Phase 2 eczema trial, TSLP program droppedAclaris Therapeutics announced that its experimental antibody bosakitug (ATI-045) did not meet the primary endpoint in a Phase 2 study for moderate-to-severe atopic dermatitis. The double‑blind Ad…
- Breckenridge Pharmaceutical recalls one lot of 60 mg propranolol extended-release capsules over possible metal contaminationBreckenridge Pharmaceutical announced a voluntary recall of a single lot of 60 mg propranolol hydrochloride extended‑release capsules that were produced by Adare Pharma Solutions because of potenti…